Trials / Enrolling By Invitation
Enrolling By InvitationNCT06646978
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 787 (estimated)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Imatinib is a tyrosine kinase inhibitor that has improved the prognosis of patients with chronic myeloid leukemia (CML). CML has become a chronic disease requiring long-term administration of imatinib. Late adverse effects were initially unknown. Since 2005, imatinib has been suspected to increase the risk of second primary malignancies (SPM). Through the French "STI571 Prospective Randomized Trial" (SPIRIT), we studied the incidence of SPM after more than 20 years of exposure, and treatment strategies for CML and SPM at their occurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib (STI571) | Imatinib-based regimen |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-05-01
- Completion
- 2025-05-01
- First posted
- 2024-10-17
- Last updated
- 2024-10-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06646978. Inclusion in this directory is not an endorsement.